Argeris N. Karabelas - 01 Jul 2024 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role
Director
Signature
/s/ Patrick J. Christmas as attorney-in-fact
Issuer symbol
RGNX
Transactions as of
01 Jul 2024
Net transactions value
-$75,091
Form type
4
Filing time
03 Jul 2024, 07:55:20 UTC
Previous filing
04 Jun 2024
Next filing
30 Jul 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGNX Common Stock Options Exercise $37,600 +10,000 +89% $3.76* 21,286 01 Jul 2024 Direct F1
transaction RGNX Common Stock Sale $112,691 -10,000 -47% $11.27 11,286 01 Jul 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGNX Stock Options (Right to Buy) Options Exercise $0 -10,000 -25% $0.000000 30,000 01 Jul 2024 Common Stock 10,000 $3.76 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $10.98 to $11.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The previously granted option, representing a right to purchase a total of 40,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2015, and the balance vested in equal monthly installments over the 24 months thereafter.